The Relationship Between Advanced Lung Cancer Inflammation Index and Adverse Clinical Outcomes in Patients with Myocardial Infarction with No-Obstructive Coronary Arteries

The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association between ALI and the prognosis of patients with myocardial infarction with no-obstructive coronary arteries (MINOCA) remains undetermined. In th...

Full description

Saved in:
Bibliographic Details
Published inJournal of inflammation research Vol. 18; no. Issue 1; pp. 9907 - 9917
Main Authors Zhao, Hong-wei, Wang, Cheng-fu
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 2025
Taylor & Francis Ltd
Dove
Dove Medical Press
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association between ALI and the prognosis of patients with myocardial infarction with no-obstructive coronary arteries (MINOCA) remains undetermined. In the present study, we consecutively included 437 MINOCA patients. All the patients received a follow-up at 1 week, 1, 3, 6, and 12 months and annually after discharge. The major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause mortality, coronary revascularization, non-fatal stroke, AMI, heart failure or readmission for angina pectoris were recorded. The predictors for MACCE were explored. The ROC analysis was used to determine the predictive value of ALI for MACCE in MINOCA patients. Patients with MACCE had a decreased level of body mass index, albumin and ALI, while an increased level of white blood cell count, neutrophils count, N-terminal proB-type natriuretic peptide, neutrophil-to-lymphocyte ratio, peak cardiac troponin I (P<0.05). When the patients were divided into three groups according the tertiles of ALI, we discovered that patients with a lower level of ALI tended to suffer an increased risk of readmission for angina pectoris and accumulative MACCE (p<0.05). The multivariate Cox hazard proportional model showed that a higher NT-proBNP (HR: 1.014, 95% CI: 1.004-1.023, P=0.005) and a lower ALI (HR: 0.997, 95% CI: 0.995-0.998, P<0.001) were independent predictors for MACCE in MINOCA patients (p<0.05). When ALI≤256.97, the specificity was 0.659 and the sensitivity 0.629 (AUC, 0.662; 95% CI, 0.611-0.714, P=0.026). A lower ALI was an independent predictor for MACCE in MINOCA patients. As a quite easily calculated indicator in clinical practice, ALI can be used in risk stratification and prognostic assessment in MINOCA patients.
AbstractList The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association between ALI and the prognosis of patients with myocardial infarction with no-obstructive coronary arteries (MINOCA) remains undetermined. In the present study, we consecutively included 437 MINOCA patients. All the patients received a follow-up at 1 week, 1, 3, 6, and 12 months and annually after discharge. The major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause mortality, coronary revascularization, non-fatal stroke, AMI, heart failure or readmission for angina pectoris were recorded. The predictors for MACCE were explored. The ROC analysis was used to determine the predictive value of ALI for MACCE in MINOCA patients. Patients with MACCE had a decreased level of body mass index, albumin and ALI, while an increased level of white blood cell count, neutrophils count, N-terminal proB-type natriuretic peptide, neutrophil-to-lymphocyte ratio, peak cardiac troponin I (P<0.05). When the patients were divided into three groups according the tertiles of ALI, we discovered that patients with a lower level of ALI tended to suffer an increased risk of readmission for angina pectoris and accumulative MACCE (p<0.05). The multivariate Cox hazard proportional model showed that a higher NT-proBNP (HR: 1.014, 95% CI: 1.004-1.023, P=0.005) and a lower ALI (HR: 0.997, 95% CI: 0.995-0.998, P<0.001) were independent predictors for MACCE in MINOCA patients (p<0.05). When ALI≤256.97, the specificity was 0.659 and the sensitivity 0.629 (AUC, 0.662; 95% CI, 0.611-0.714, P=0.026). A lower ALI was an independent predictor for MACCE in MINOCA patients. As a quite easily calculated indicator in clinical practice, ALI can be used in risk stratification and prognostic assessment in MINOCA patients.
The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association between ALI and the prognosis of patients with myocardial infarction with no-obstructive coronary arteries (MINOCA) remains undetermined.BackgroundThe advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association between ALI and the prognosis of patients with myocardial infarction with no-obstructive coronary arteries (MINOCA) remains undetermined.In the present study, we consecutively included 437 MINOCA patients. All the patients received a follow-up at 1 week, 1, 3, 6, and 12 months and annually after discharge. The major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause mortality, coronary revascularization, non-fatal stroke, AMI, heart failure or readmission for angina pectoris were recorded. The predictors for MACCE were explored. The ROC analysis was used to determine the predictive value of ALI for MACCE in MINOCA patients.MethodsIn the present study, we consecutively included 437 MINOCA patients. All the patients received a follow-up at 1 week, 1, 3, 6, and 12 months and annually after discharge. The major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause mortality, coronary revascularization, non-fatal stroke, AMI, heart failure or readmission for angina pectoris were recorded. The predictors for MACCE were explored. The ROC analysis was used to determine the predictive value of ALI for MACCE in MINOCA patients.Patients with MACCE had a decreased level of body mass index, albumin and ALI, while an increased level of white blood cell count, neutrophils count, N-terminal proB-type natriuretic peptide, neutrophil-to-lymphocyte ratio, peak cardiac troponin I (P<0.05). When the patients were divided into three groups according the tertiles of ALI, we discovered that patients with a lower level of ALI tended to suffer an increased risk of readmission for angina pectoris and accumulative MACCE (p<0.05). The multivariate Cox hazard proportional model showed that a higher NT-proBNP (HR: 1.014, 95% CI: 1.004-1.023, P=0.005) and a lower ALI (HR: 0.997, 95% CI: 0.995-0.998, P<0.001) were independent predictors for MACCE in MINOCA patients (p<0.05). When ALI≤256.97, the specificity was 0.659 and the sensitivity 0.629 (AUC, 0.662; 95% CI, 0.611-0.714, P=0.026).ResultsPatients with MACCE had a decreased level of body mass index, albumin and ALI, while an increased level of white blood cell count, neutrophils count, N-terminal proB-type natriuretic peptide, neutrophil-to-lymphocyte ratio, peak cardiac troponin I (P<0.05). When the patients were divided into three groups according the tertiles of ALI, we discovered that patients with a lower level of ALI tended to suffer an increased risk of readmission for angina pectoris and accumulative MACCE (p<0.05). The multivariate Cox hazard proportional model showed that a higher NT-proBNP (HR: 1.014, 95% CI: 1.004-1.023, P=0.005) and a lower ALI (HR: 0.997, 95% CI: 0.995-0.998, P<0.001) were independent predictors for MACCE in MINOCA patients (p<0.05). When ALI≤256.97, the specificity was 0.659 and the sensitivity 0.629 (AUC, 0.662; 95% CI, 0.611-0.714, P=0.026).A lower ALI was an independent predictor for MACCE in MINOCA patients. As a quite easily calculated indicator in clinical practice, ALI can be used in risk stratification and prognostic assessment in MINOCA patients.ConclusionA lower ALI was an independent predictor for MACCE in MINOCA patients. As a quite easily calculated indicator in clinical practice, ALI can be used in risk stratification and prognostic assessment in MINOCA patients.
Hong-wei Zhao,1 Cheng-fu Wang2 1Department of Cardiology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, People’s Republic of China; 2Department of Cardiology, The People’s Hospital of Liaoning Province, Shenyang, People’s Republic of ChinaCorrespondence: Hong-wei Zhao, Email zhaohongwei@sysush.comBackground: The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association between ALI and the prognosis of patients with myocardial infarction with no-obstructive coronary arteries (MINOCA) remains undetermined.Methods: In the present study, we consecutively included 437 MINOCA patients. All the patients received a follow-up at 1 week, 1, 3, 6, and 12 months and annually after discharge. The major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause mortality, coronary revascularization, non-fatal stroke, AMI, heart failure or readmission for angina pectoris were recorded. The predictors for MACCE were explored. The ROC analysis was used to determine the predictive value of ALI for MACCE in MINOCA patients.Results: Patients with MACCE had a decreased level of body mass index, albumin and ALI, while an increased level of white blood cell count, neutrophils count, N-terminal proB-type natriuretic peptide, neutrophil-to-lymphocyte ratio, peak cardiac troponin I (P< 0.05). When the patients were divided into three groups according the tertiles of ALI, we discovered that patients with a lower level of ALI tended to suffer an increased risk of readmission for angina pectoris and accumulative MACCE (p< 0.05). The multivariate Cox hazard proportional model showed that a higher NT-proBNP (HR: 1.014, 95% CI: 1.004– 1.023, P=0.005) and a lower ALI (HR: 0.997, 95% CI: 0.995– 0.998, P< 0.001) were independent predictors for MACCE in MINOCA patients (p< 0.05). When ALI≤ 256.97, the specificity was 0.659 and the sensitivity 0.629 (AUC, 0.662; 95% CI, 0.611– 0.714, P=0.026).Conclusion: A lower ALI was an independent predictor for MACCE in MINOCA patients. As a quite easily calculated indicator in clinical practice, ALI can be used in risk stratification and prognostic assessment in MINOCA patients.Keywords: advanced lung cancer inflammation index, myocardial infarction with no-obstructive coronary arteries, predictor, major adverse cardiovascular and cerebrovascular events
Background: The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association between ALI and the prognosis of patients with myocardial infarction with no-obstructive coronary arteries (MINOCA) remains undetermined.Methods: In the present study, we consecutively included 437 MINOCA patients. All the patients received a follow-up at 1 week, 1, 3, 6, and 12 months and annually after discharge. The major adverse cardiovascular and cerebrovascular events (MACCE) defined as a composite of all-cause mortality, coronary revascularization, non-fatal stroke, AMI, heart failure or readmission for angina pectoris were recorded. The predictors for MACCE were explored. The ROC analysis was used to determine the predictive value of ALI for MACCE in MINOCA patients.Results: Patients with MACCE had a decreased level of body mass index, albumin and ALI, while an increased level of white blood cell count, neutrophils count, N-terminal proB-type natriuretic peptide, neutrophil-to-lymphocyte ratio, peak cardiac troponin I (P< 0.05). When the patients were divided into three groups according the tertiles of ALI, we discovered that patients with a lower level of ALI tended to suffer an increased risk of readmission for angina pectoris and accumulative MACCE (p< 0.05). The multivariate Cox hazard proportional model showed that a higher NT-proBNP (HR: 1.014, 95% CI: 1.004– 1.023, P=0.005) and a lower ALI (HR: 0.997, 95% CI: 0.995– 0.998, P< 0.001) were independent predictors for MACCE in MINOCA patients (p< 0.05). When ALI≤ 256.97, the specificity was 0.659 and the sensitivity 0.629 (AUC, 0.662; 95% CI, 0.611– 0.714, P=0.026).Conclusion: A lower ALI was an independent predictor for MACCE in MINOCA patients. As a quite easily calculated indicator in clinical practice, ALI can be used in risk stratification and prognostic assessment in MINOCA patients.
Audience Academic
Author Wang, Cheng-fu
Zhao, Hong-wei
Author_xml – sequence: 1
  givenname: Hong-wei
  surname: Zhao
  fullname: Zhao, Hong-wei
– sequence: 2
  givenname: Cheng-fu
  surname: Wang
  fullname: Wang, Cheng-fu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40740972$$D View this record in MEDLINE/PubMed
BookMark eNpdkk1vEzEQQFeoiJbSE3dkiQsSSrHX9u7mhELER1AgqJSzNWvPJo42drB3U_qb-JN4k1BafPHY8_Q8tudpduK8wyx7zuhlzkT55vPs6vK75KzK2aPsjLGyGpWUs5N78Wl2EeOaDqOkIhdPslNBS0HHZX6W_b5eIbnCFjrrXVzZLXmH3Q2iIxOzA6fRkHnvlmQ6xIHMXNPCZrOn08LgLwLODCyGiGTaWmc1tGTRd9pvMBLryLdEo-siubHdiny59RqCsQlKMgh6r9qnvvrRoo5d6NPeLsl88A7CLZmEDoPF-Cx73EAb8eI4n2c_Pry_nn4azRcfZ9PJfKS5yLuRYM24qapKFEZWeQ1cjiXSmsm8oExLqaEsKMhcQiGKUpiKF6zWtSlKoIyC4OfZ7OA1HtZqG-wmVaE8WLXf8GGpIHRWt6i0KQBL1AxEI1huqroRYKRhnFdSssH19uDa9vUGjU4PEaB9IH2YcXalln6nWM7pWBbjZHh1NAT_s8fYqY2NGtsWHPo-Kp5zmX6Z0SKhL_9D174PLr3VQI2FoFzwf9QS0g2sa3w6WA9SNalkKpyJvevF_cLvKv7bOgl4fQB08DEGbO4QRtXQmyr1pjr2Jv8DHFrWaQ
Cites_doi 10.1155/2019/2513026
10.2147/CIA.S457971
10.1002/clc.23651
10.1016/j.cytogfr.2023.08.009
10.1186/s12877-017-0527-z
10.1007/s00380-017-0981-8
10.1536/ihj.24-046
10.2147/JIR.S421021
10.5603/CJ.a2020.0146
10.1161/CIR.0000000000000617
10.3389/fnut.2022.989914
10.1186/s12957-023-02972-4
10.3389/fcvm.2021.706852
10.1002/clc.70013
10.1016/j.ijcard.2019.02.036
10.2147/JIR.S482596
10.7717/peerj.10100
10.3389/fcvm.2022.934551
10.1016/j.ejim.2018.04.014
10.1093/eurheartj/ehw149
10.1161/JAHA.118.009174
10.2147/JIR.S411086
10.1161/CIRCULATIONAHA.114.011201
10.3389/fcvm.2024.1367919
10.1016/j.amjcard.2015.06.011
10.1186/1471-2407-13-158
10.1373/clinchem.2018.301085
10.1186/s12872-021-02236-7
10.1186/s12872-023-03608-x
10.1002/ehf2.13640
10.1016/j.hrtlng.2021.07.007
10.5114/aic.2024.142239
10.1016/j.jjcc.2016.05.009
10.1177/2047487319883723
10.1093/eurheartj/ehad191
10.3390/jcm13206059
10.1111/j.1365-2796.2012.02591.x
ContentType Journal Article
Copyright 2025 Zhao and Wang.
COPYRIGHT 2025 Dove Medical Press Limited
2025. This work is licensed under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025 Zhao and Wang. 2025 Zhao and Wang.
Copyright_xml – notice: 2025 Zhao and Wang.
– notice: COPYRIGHT 2025 Dove Medical Press Limited
– notice: 2025. This work is licensed under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025 Zhao and Wang. 2025 Zhao and Wang.
DBID AAYXX
CITATION
NPM
3V.
7RV
7XB
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
KB0
LK8
M2O
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.2147/JIR.S531821
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central (New)
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
Nursing & Allied Health Database (Alumni Edition)
ProQuest Biological Science Collection
ProQuest research library
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Zhao and Wang
EISSN 1178-7031
EndPage 9917
ExternalDocumentID oai_doaj_org_article_cd6ae7ec1a4f412d8bf4ad5d13385514
PMC12309569
A853381406
40740972
10_2147_JIR_S531821
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: ;
GroupedDBID ---
0YH
29K
2WC
53G
5VS
7RV
8FE
8FH
8FI
8FJ
8G5
AAYXX
ABUWG
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BKEYQ
BPHCQ
BVXVI
CCPQU
CITATION
D-I
DIK
DWQXO
E3Z
EBD
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
LK8
M2O
M48
M7P
M~E
NAPCQ
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PPXIY
PQGLB
PQQKQ
PROAC
RIG
RNS
RPM
TDBHL
TR2
UKHRP
VDV
NPM
PUEGO
3V.
7XB
8FK
MBDVC
PKEHL
PQEST
PQUKI
Q9U
7X8
5PM
ID FETCH-LOGICAL-c342t-41f9f88846d582ba3595e0b152601c55ca760a525a64674d8361bcbd67a010a43
IEDL.DBID M48
ISSN 1178-7031
IngestDate Wed Aug 27 01:10:13 EDT 2025
Thu Aug 21 18:33:38 EDT 2025
Thu Jul 31 18:31:34 EDT 2025
Thu Aug 14 21:19:13 EDT 2025
Wed Aug 27 16:51:43 EDT 2025
Sun Aug 03 01:51:17 EDT 2025
Thu Jul 31 00:24:28 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Issue 1
Keywords major adverse cardiovascular and cerebrovascular events
myocardial infarction with no-obstructive coronary arteries
predictor
advanced lung cancer inflammation index
Language English
License https://creativecommons.org/licenses/by-nc/3.0
2025 Zhao and Wang.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c342t-41f9f88846d582ba3595e0b152601c55ca760a525a64674d8361bcbd67a010a43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/JIR.S531821
PMID 40740972
PQID 3239440343
PQPubID 3933408
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_cd6ae7ec1a4f412d8bf4ad5d13385514
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12309569
proquest_miscellaneous_3235031106
proquest_journals_3239440343
gale_infotracmisc_A853381406
pubmed_primary_40740972
crossref_primary_10_2147_JIR_S531821
PublicationCentury 2000
PublicationDate 2025-00-00
PublicationDateYYYYMMDD 2025-01-01
PublicationDate_xml – year: 2025
  text: 2025-00-00
PublicationDecade 2020
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
– name: Macclesfield
PublicationTitle Journal of inflammation research
PublicationTitleAlternate J Inflamm Res
PublicationYear 2025
Publisher Dove Medical Press Limited
Taylor & Francis Ltd
Dove
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Taylor & Francis Ltd
– name: Dove
– name: Dove Medical Press
References Sh (ref11) 2013; 13
Abdu (ref6) 2019; 287
Beltrame (ref1) 2013; 273
Stangret (ref23) 2023; 74
Hjort (ref9) 2019; 65
Shen (ref37) 2021; 50
Pasupathy (ref2) 2015; 131
Ah (ref21) 2024; 20
Shan (ref35) 2024; 2024
Lopez-Pais (ref7) 2022; 29
Ji (ref27) 2021; 8
Agewall (ref3) 2017; 38
Dong (ref32) 2024; 47
Byrne (ref38) 2023; 44
Yoo (ref29) 2017; 69
Xie (ref14) 2020; 8
Zhang (ref13) 2019; 2019
Chen (ref26) 2023; 16
Daniel (ref4) 2015; 116
Hou (ref8) 2024; 17
Yoshioka (ref36) 2021; 8
Liu (ref12) 2023; 21
Wu (ref28) 2024; 19
Arques (ref34) 2018; 52
Yuan (ref19) 2022; 9
Am (ref25) 2021; 21
Trimarchi (ref17) 2024; 13
Shi (ref20) 2023; 23
Zhao (ref15) 2024; 65
Km (ref10) 2021; 44
Zhang (ref18) 2022; 9
Thygesen (ref22) 2018; 138
Safdar (ref5) 2018; 7
Wang (ref16) 2023; 16
Alzahrani (ref30) 2017; 17
Ando (ref31) 2020; 27
Wada (ref33) 2017; 32
Zhou (ref24) 2024; 11
References_xml – volume: 2019
  start-page: 2513026
  year: 2019
  ident: ref13
  publication-title: Dis Markers
  doi: 10.1155/2019/2513026
– volume: 19
  start-page: 705
  year: 2024
  ident: ref28
  publication-title: Clin Interv Aging
  doi: 10.2147/CIA.S457971
– volume: 44
  start-page: 1019
  year: 2021
  ident: ref10
  publication-title: Clin Cardiol
  doi: 10.1002/clc.23651
– volume: 74
  start-page: 76
  year: 2023
  ident: ref23
  publication-title: Cytokine Growth Factor Rev
  doi: 10.1016/j.cytogfr.2023.08.009
– volume: 17
  start-page: 136
  year: 2017
  ident: ref30
  publication-title: BMC Geriatr
  doi: 10.1186/s12877-017-0527-z
– volume: 32
  start-page: 1085
  year: 2017
  ident: ref33
  publication-title: Heart Vessels
  doi: 10.1007/s00380-017-0981-8
– volume: 65
  start-page: 621
  year: 2024
  ident: ref15
  publication-title: Int Heart J
  doi: 10.1536/ihj.24-046
– volume: 16
  start-page: 3631
  year: 2023
  ident: ref16
  publication-title: J Inflamm Res
  doi: 10.2147/JIR.S421021
– volume: 29
  start-page: 798
  year: 2022
  ident: ref7
  publication-title: Cardiol J
  doi: 10.5603/CJ.a2020.0146
– volume: 138
  start-page: e618
  year: 2018
  ident: ref22
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000000617
– volume: 9
  start-page: 989914
  year: 2022
  ident: ref18
  publication-title: Front Nutr
  doi: 10.3389/fnut.2022.989914
– volume: 2024
  start-page: AT10578
  year: 2024
  ident: ref35
  publication-title: Altern Ther Health Med
– volume: 21
  start-page: 81
  year: 2023
  ident: ref12
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-023-02972-4
– volume: 8
  start-page: 706852
  year: 2021
  ident: ref27
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2021.706852
– volume: 47
  start-page: e70013
  year: 2024
  ident: ref32
  publication-title: Clin Cardiol
  doi: 10.1002/clc.70013
– volume: 287
  start-page: 27
  year: 2019
  ident: ref6
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2019.02.036
– volume: 17
  start-page: 8281
  year: 2024
  ident: ref8
  publication-title: J Inflamm Res
  doi: 10.2147/JIR.S482596
– volume: 8
  start-page: e10100
  year: 2020
  ident: ref14
  publication-title: PeerJ
  doi: 10.7717/peerj.10100
– volume: 9
  start-page: 934551
  year: 2022
  ident: ref19
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2022.934551
– volume: 52
  start-page: 8
  year: 2018
  ident: ref34
  publication-title: Eur J Intern Med
  doi: 10.1016/j.ejim.2018.04.014
– volume: 38
  start-page: 143
  year: 2017
  ident: ref3
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehw149
– volume: 7
  start-page: e009174
  year: 2018
  ident: ref5
  publication-title: J Am Heart Assoc
  doi: 10.1161/JAHA.118.009174
– volume: 16
  start-page: 2051
  year: 2023
  ident: ref26
  publication-title: J Inflamm Res
  doi: 10.2147/JIR.S411086
– volume: 131
  start-page: 861
  year: 2015
  ident: ref2
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.114.011201
– volume: 11
  start-page: 1367919
  year: 2024
  ident: ref24
  publication-title: Front Cardiovasc Med
  doi: 10.3389/fcvm.2024.1367919
– volume: 116
  start-page: 838
  year: 2015
  ident: ref4
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2015.06.011
– volume: 13
  start-page: 158
  year: 2013
  ident: ref11
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-13-158
– volume: 65
  start-page: 1023
  year: 2019
  ident: ref9
  publication-title: Clin Chem
  doi: 10.1373/clinchem.2018.301085
– volume: 21
  start-page: 422
  year: 2021
  ident: ref25
  publication-title: BMC Cardiovasc Disord
  doi: 10.1186/s12872-021-02236-7
– volume: 23
  start-page: 565
  year: 2023
  ident: ref20
  publication-title: BMC Cardiovasc Disord
  doi: 10.1186/s12872-023-03608-x
– volume: 8
  start-page: 5456
  year: 2021
  ident: ref36
  publication-title: ESC Heart Fail
  doi: 10.1002/ehf2.13640
– volume: 50
  start-page: 863
  year: 2021
  ident: ref37
  publication-title: Heart Lung
  doi: 10.1016/j.hrtlng.2021.07.007
– volume: 20
  start-page: 277
  year: 2024
  ident: ref21
  publication-title: Postepy Kardiol Interwencyjnej
  doi: 10.5114/aic.2024.142239
– volume: 69
  start-page: 555
  year: 2017
  ident: ref29
  publication-title: J Cardiol
  doi: 10.1016/j.jjcc.2016.05.009
– volume: 27
  start-page: 2229
  year: 2020
  ident: ref31
  publication-title: Eur J Prev Cardiol
  doi: 10.1177/2047487319883723
– volume: 44
  start-page: 3720
  year: 2023
  ident: ref38
  publication-title: Eur Heart J
  doi: 10.1093/eurheartj/ehad191
– volume: 13
  start-page: 6059
  year: 2024
  ident: ref17
  publication-title: J Clin Med
  doi: 10.3390/jcm13206059
– volume: 273
  start-page: 182
  year: 2013
  ident: ref1
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2012.02591.x
SSID ssj0000070424
Score 2.3130448
Snippet The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the association...
Background: The advanced lung cancer inflammation index (ALI) has been suggested as a reliable prognostic indicator for cardiovascular disease. However, the...
Hong-wei Zhao,1 Cheng-fu Wang2 1Department of Cardiology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, People’s Republic of China;...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 9907
SubjectTerms advanced lung cancer inflammation index
Albumin
Angina
Angina pectoris
Antilipemic agents
Arteries
Blood
Blood cell count
Body mass index
Cardiac function
Cardiac patients
Cardiovascular diseases
Care and treatment
Cerebral infarction
China
Clinical outcomes
Congestive heart failure
Coronary artery
Coronary artery bypass
Coronary vessels
Heart attack
Heart attacks
Heart failure
Hospitals
Hypertension
Inflammation
Kinases
Laboratories
Leukocytes (neutrophilic)
Lung cancer
Lymphocytes
major adverse cardiovascular and cerebrovascular events
Medical prognosis
Mortality
Myocardial infarction
myocardial infarction with no-obstructive coronary arteries
Natriuretic peptides
Neutrophils
Normal distribution
Original Research
Patient outcomes
Population
predictor
Prognosis
Regression analysis
Risk factors
Troponin I
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYqDlUvVUtfoYBciWvKJn4lxwUVAepC1RaJm-WnWAllEVkQ_Kb-yc7EZrURh156S-LEcjLfeGbi8TeE7LVBORVaXGFktuRK-BJZoEoWhYshOmMt7h2encnjC356KS7XSn1hTliiB04fbt95aYIKrjI88qr2jY3ceOExtkJrj7Mv2Ly1YCo5vgrX9NKGPCzFs3968vPrLwBcU1cjEzQw9T-fj9cM0jhZcs36HL0hr7PbSKdpuG_Ji9BtkpezvDD-jvwBcdNVYtvV_IYepAQsOs2L_PQ7qDU9xONbetJFQELatQgnPjxQ03k6VGfuA81kodf0_G4JiAw9nXf0R2Jg7Sn-uqWzRzCCCK5r7Ay0ZehqaDpblOc289LeQ2fIkWBuH3HwyKrcvycXR99-Hx6XuQ5D6RivlyDG2EaIlLn0oqmtwb28YWLB8kM054RwRsmJEbUwEmuX-IbJyjrrpTIQ7RnOPpCNbtGFT4SaxgRwiJiJ0vLYtE2YNE4GVZm6hcdUQfaeRKNvEt2GhjAFJahBgjpLsCAHKLbVLciRPVwA5OiMHP0v5BRkG4WuUZNBsg70yukpuC8MWcAkND-BQWe97jXDSvJ8wjgryJdVMz6JuWpdWNwN9wiYKivs4mPCzmqgED4jwVhdkGaEqtGbjFu6-dXA-g0uBpJGtlv_490_k1c1FjIe_iVtkw3ARNgB72ppdwdF-gtRiyWy
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central (New)
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY99z1w0N-uo1tiRbfhpJaWnLkpZuhb4Jfa6BYmdxWta_af_k7mwlqxnszbFsIed3J92dTr8jZK_ypS19hTuMzKS8FC5FFqiUBWGDD1Ybg2eHp7Pi-JKfXomrGHBrY1rlek7sJmrXWIyR7zOs4c1HjLMvi58pVo3C3dVYQuMx2YYpWILztT05nJ1fbKIsyGbDc94fzMOSPPunJxefv4HgyTwbLEUdY_-_8_KDhWmYNPlgFTp6Tp5F85GOe7xfkEe-fkmeTOMG-SvyG2CnmwS36_mCTvpELDqOm_30K6g3PcDrJT2pA0hEf3oRfjj_i-ra0a5Kc-tpJA29oWe3K_iXfEvnNT3vmVhbiiFcOr2HxRCF7AY7A63puuqaZk16ZiI_7R10hlwJenmPg0d25fY1uTw6_H5wnMZ6DKllPF8BnKEK4DHzwgmZG41nev3IgAUAXp0VwuqyGGmRC11gDRMnWZEZa1xRavD6NGdvyFbd1P4doVpqD4YR06EwPMhK-pG0hS8znVfwWpmQvTU0atHTbihwVxBBBQiqiGBCJgjb5hHkyu5uNMsfKqqesq7QvvQ20zzwLHfSBK6dcOido72YkF0EXaFGA7IW9MuqMZgxDNnACmheC4OK-t2qv9KYkE-bZnwTc9Zq39x2zwiYMjPs4m0vO5uBghuNRGN5QuRAqgZfMmyp59cd-zeYGkgeWe38f1zvydMcSxV30aJdsgVo-w9gP63Mx6gkfwCIKx3D
  priority: 102
  providerName: ProQuest
Title The Relationship Between Advanced Lung Cancer Inflammation Index and Adverse Clinical Outcomes in Patients with Myocardial Infarction with No-Obstructive Coronary Arteries
URI https://www.ncbi.nlm.nih.gov/pubmed/40740972
https://www.proquest.com/docview/3239440343
https://www.proquest.com/docview/3235031106
https://pubmed.ncbi.nlm.nih.gov/PMC12309569
https://doaj.org/article/cd6ae7ec1a4f412d8bf4ad5d13385514
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELamTUK8IH4TGJWR9prRJI7tPCDUThvbRLtpUKlvlu3YW6UqHU2H1r-Jf5I7J60W4IGXqq1jN-1917uz774j5KBwwgpX4AljZmIm8jJGFqg487n1zlttDNYOj8b8dMLOp_l0h2yacbY_YP3P0A77SU2W88P7H-vPoPCfMI05YeLj-dnV4TfAksSC8j0wSQI1dNT6-Y0fLPCIr2m0ImPkbG9q9f6c37FOgcT_77_qB7aqm0f5wDCdPCVPWo-SDhoIPCM7rnpOHo3aM_MX5BcggW5z3m5mt3TY5GbRQXv-T7-CxtMjfL6kZ5UHkDQFjfCidPdUVyUNjZtrR1se0Tm9uFsBWF1NZxW9bMhZa4q7unS0BvuIuJvjYqBIYakwNF7EF6alrP0JiyF9gl6u8eaRcLl-SSYnx9-PTuO2RUNsM5auQMK-8BBEM17mMjUay3xd34BTAIGezXOrBe_rPM01x7Ympcx4YqwpudAQCGqWvSK71aJybwjVUjvwlTLtuWFeFtL1peVOJDotYJqIyMFGNOq2YeJQEMGgBBVIULUSjMgQxba9BOmzwxuL5bVqtVHZkmsnnE008yxJS2k802VeYsCOLmRE9lHoCmEHkrWgclYNwLPJkCCMw_AGDGqDWJVhk3nWz1gWkQ_bYZyJaWyVW9yFa3LAXoJLvG6ws71RiKyReyyNiOygqvNNuiPV7CYQgoP3gXySxdv_-OB35HGKLYzDLtI-2QWRu_fgV61Mj-wNj8eXV72wLwGPX6ZJL-jRbyIeJbE
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKKgEXxJuFAkYqx6VZ2_s6IJSUVkmbpFVppd5cv5ZGqnZDNgXym5D4jczsIzRC4tbbZu21HH3jedjjbwjZTl1sYpfiCSPXvohD6yMLlM-z0GQuM0prvDs8nkSDM3FwHp5vkN_tXRhMq2x1YqWobWFwj3yHYw1v0eWCf5p987FqFJ6utiU0arE4dMsfELKVH4efAd_3jO3vne4O_KaqgG-4YAuYVJZmEPeJyIYJ0wpvprquBjsGsYkJQ6PiqKtCFqoIK3HYhEeBNtpGsYLYRQkO494hm4JD9w7Z7O9Njk9WuzrIniOYqC8CYgmgnYPhyYcvIOgJC9ZMX1Uh4F87cMMQridp3rB6-w_Jg8Zdpb1avh6RDZc_JnfHzYH8E_ILxIyuEuoupzParxO_aK9JLqAjUCd0F5_ndJhnIIH1bUn4Yd1PqnJLq6rQpaMNSekVPbpeACqupNOcHtfMryXFLWM6XoLxRaG-wsEAjmqoqmlS-Ee64cP9DoMhN4OaL3HyyOZcPiVnt4LUM9LJi9y9IFQlyoEjxlUWaZElaeK6iYlcHCiWwmexR7ZbaOSspvmQEB4hghIQlA2CHukjbKsuyM1dvSjmX2Wz1KWxkXKxM4ESmQiYTXQmlA0t7gagf-qRLQRdogYBZA2sZyN74DZxZB-LoLkVBtnok1L-lX6PvFs145eYI5e74rrqE4KKDnCI57XsrCYKYTsSmzGPJGtStfZP1lvy6WXFNg6uDZJVpi__P6-35N7gdDySo-Hk8BW5z7BMcrVTtUU6gLx7Db7bQr9pFgwlF7e9Rv8ADcJYag
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbhMxFLVKKlVsEG9CCxipLIdkPJ7XAqGkbdS0TRoVKnXn-kkjVZM0kwL5Jv6Ar-PeGSc0QmLXXRLPWI7OfdrX5xKym9tUpzbHE8ZIBTyNTYAsUEHkYu2s01IpvDs8GCaH5_zoIr7YIL-Xd2GwrHJpEytDbSYa98hbEfbw5u2IRy3nyyJG-73P05sAO0jhSeuynUYtIsd28QPSt_JTfx-w_sBY7-Dr3mHgOwwEOuJsDgt0uYMckCcmzpiSeEvVthX4NMhTdBxrmSZtGbNYJtiVw2RREiqtTJJKyGMkj2DeB2Qzhayo3SCb3YPh6Gy1w4NMOpzx-lIgtgNqHfXPPn4Boc9YuOYGq24B__qEO05xvWDzjgfsPSaPfOhKO7WsPSEbtnhKtgb-cP4Z-QUiR1fFdVfjKe3WRWC04wsN6AmYFrqHn2e0XziQxvrmJHwx9ieVhaFVh-jSUk9Yek1Pb-eAkC3puKCjmgW2pLh9TAcLcMQo4Nc4GcBRTVUNDSfBqfLcuN9hMuRpkLMFLh6Zncvn5PxekHpBGsWksK8IlZm0EJRF0iWKuyzPbDvTiU1DyXJ4LW2S3SU0YlpTfghIlRBBAQgKj2CTdBG21SPI0139MJl9E17thTaJtKnVoeSOh8xkynFpYoM7AxirNskOgi7QmgCyGnRbiw6EUBEykSUwvBQG4W1LKf5qQpO8Xw3jm1gvV9jJbfVMDOY6xCle1rKzWigIK5KcsSbJ1qRq7Z-sjxTjq4p5HMIcJK7MX_9_Xe_IFuimOOkPj7fJQ4Ydk6tNqx3SAODtGwjj5uqt1xdKLu9bRf8ACpZcnw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Relationship+Between+Advanced+Lung+Cancer+Inflammation+Index+and+Adverse+Clinical+Outcomes+in+Patients+with+Myocardial+Infarction+with+No-Obstructive+Coronary+Arteries&rft.jtitle=Journal+of+inflammation+research&rft.au=Zhao%2C+Hong-Wei&rft.au=Wang%2C+Cheng-Fu&rft.date=2025&rft.issn=1178-7031&rft.eissn=1178-7031&rft.volume=18&rft.spage=9907&rft_id=info:doi/10.2147%2FJIR.S531821&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7031&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7031&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7031&client=summon